In last trading session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) saw 0.54 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price level of $11.63 trading at $0.04 or 0.35% at ring of the bell on the day assigns it a market valuation of $792.64M. That closing price of EYPT’s stock is at a discount of -166.47% from its 52-week high price of $30.99 and is indicating a premium of 49.61% from its 52-week low price of $5.86. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.61 million shares which gives us an average trading volume of 742.60K if we extend that period to 3-months.
For EyePoint Pharmaceuticals Inc (EYPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.08. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Upright in the green during last session for gaining 0.35%, in the last five days EYPT remained trading in the red while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $11.63 price level, adding 6.96% to its value on the day. EyePoint Pharmaceuticals Inc’s shares saw a change of -49.68% in year-to-date performance and have moved -3.57% in past 5-day. EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) showed a performance of 41.14% in past 30-days. Number of shares sold short was 9.17 million shares which calculate 15.84 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 61.23% to its current value. Analysts have been projecting 30 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -157.95% in reaching the projected high whereas dropping to the targeted low would mean a loss of -157.95% for stock’s current value.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Statistics highlight that EyePoint Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -3.80% of value to its shares in past 6 months, showing an annual growth rate of -25.82% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.57% during past 5 years.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
Insiders are in possession of 1.14% of company’s total shares while institution are holding 86.48 percent of that, with stock having share float percentage of 87.48%. Investors also watch the number of corporate investors in a company very closely, which is 86.48% institutions for EyePoint Pharmaceuticals Inc that are currently holding shares of the company. CORMORANT ASSET MANAGEMENT, LP is the top institutional holder at EYPT for having 8.32 million shares of worth $72.43 million. And as of 2024-06-30, it was holding 15.7334 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 5.18 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7818 of outstanding shares, having a total worth of $45.03 million.
